Immuron shares fall 10.97% premarket after announcing 45.47M securities issue to strengthen market position.

Immuron (IMRN) fell 10.97% in premarket trading following the announcement of a proposed securities issue to raise capital, which may dilute existing shareholders and signal financial pressure despite positive developments in its DoD-funded vaccine programs. While the company secured new U.S. Department of Defense awards to develop therapeutics for Campylobacter and Shigella and is awaiting clinical trial results for its Travelan® product, the decision to issue 45.47 million ordinary shares appears to have overshadowed these advancements in the market’s short-term assessment.